You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Natco Pharma launches gastric cancer tablet in India

Capital Market 

Natco Pharma on Thursday announced that it has launched a tablet for the treatment of advanced colorectal and gastric cancer in India.

In a regulatory filing, Natco Pharma announced the launch a novel fixed-dose combination of Trifluridine and Tipiracil under the brand name Tipanat as a pack of 20 tablets in a bottle. Tipanat is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer.

In India, approximately 1,25,000 new cases of colorectal and gastric cancer cancers are reported every year. Tipanat is of high importance in not only extending the survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need. Natco said it is offering Tipanat at an affordable price.

In a separate press release, Natco Pharma announced that its marketing partner Breckenridge Pharmaceutical, Inc. has launched the everolimus tablets (generic for Afinitor) in the US market. According to industry sales data, the 10mg strength of Afinitor generated annual sales of $392 million during the twelve months ending July 2021. Everolimus is used to treat various types of cancer.

Natco Pharma manufactures a comprehensive range of branded and generic dosage forms, bulk actives and intermediates for both Indian as well as International markets. The company's consolidated net profit tumbled 68.1% to Rs 65.10 crore on a 53% drop in net sales to Rs 377.20 crore in Q2 FY22 over Q2 FY21.

Shares of Natco Pharma ended 0.8% lower at Rs 814.70 on Thursday. The domestic stock market is shut today on account of Guru Nanak Jayanti.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 19 2021. 09:27 IST